The "neurotrophin hypothesis" of depression posits a role of brain-derived neurotrophic factor (BDNF) in depression, although it is unknown whether BDNF is more involved in the etiology of depression or in the mechanism of action of antidepressants. It is also unknown whether pre-treatment serum BDNF levels predict antidepressant response. Methods: Thirty un-medicated depressed subjects were treated with escitalopram (N= 16) or sertraline (N= 14) for 8 weeks. Twenty-five of the depressed subjects completed 8 weeks of antidepressant treatment and had analyzable data. Twenty-eight healthy controls were also studied. Serum for BDNF assay was obtained at baseline in all subjects and after 8 weeks of treatment in the depressed subjects. Depression ratings were obtained at baseline and after 8 weeks of treatment in the depressed subjects. Results: Pre-treatment BDNF levels were lower in the depressed subjects than the controls (p= 0.001) but were not significantly correlated with pre-treatment depression severity. Depression ratings improved with SSRI treatment (pb 0.001), and BDNF levels increased with treatment (p= 0.005). Changes in BDNF levels were not significantly correlated with changes in depression ratings. However, pre-treatment BDNF levels were directly correlated with antidepressant responses (pb 0.01), and "Responders" to treatment (≥50% improvement in depression ratings) had higher pre-treatment BDNF levels than did "Non-responders" (pb 0.05). Conclusions: These results confirm low serum BDNF levels in un-medicated depressed subjects and confirm antidepressant-induced increases in BDNF levels, but they suggest that antidepressants do not work simply by correcting BDNF insufficiency. Rather, these findings are consistent with a permissive or facilitatory role of BDNF in the mechanism of action of antidepressants.
Objectives:
The "neurotrophin hypothesis" of depression posits a role of brain-derived neurotrophic factor (BDNF) in depression, although it is unknown whether BDNF is more involved in the etiology of depression or in the mechanism of action of antidepressants. It is also unknown whether pre-treatment serum BDNF levels predict antidepressant response. Methods: Thirty un-medicated depressed subjects were treated with escitalopram (N= 16) or sertraline (N= 14) for 8 weeks. Twenty-five of the depressed subjects completed 8 weeks of antidepressant treatment and had analyzable data. Twenty-eight healthy controls were also studied. Serum for BDNF assay was obtained at baseline in all subjects and after 8 weeks of treatment in the depressed subjects. Depression ratings were obtained at baseline and after 8 weeks of treatment in the depressed subjects. Results: Pre-treatment BDNF levels were lower in the depressed subjects than the controls (p= 0.001) but were not significantly correlated with pre-treatment depression severity. Depression ratings improved with SSRI treatment (pb 0.001), and BDNF levels increased with treatment (p= 0.005). Changes in BDNF levels were not significantly correlated with changes in depression ratings. However, pre-treatment BDNF levels were directly correlated with antidepressant responses (pb 0.01), and "Responders" to treatment (≥50% improvement in depression ratings) had higher pre-treatment BDNF levels than did "Non-responders" (pb 0.05). Conclusions: These results confirm low serum BDNF levels in un-medicated depressed subjects and confirm antidepressant-induced increases in BDNF levels, but they suggest that antidepressants do not work simply by correcting BDNF insufficiency. Rather, these findings are consistent with a permissive or facilitatory role of BDNF in the mechanism of action of antidepressants.
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Introduction
Brain-derived neurotrophic factor (BDNF) is an important regulatory protein in neurodevelopment, in synaptogenesis and neurogenesis and in protecting the viability of newly differentiated neurons (Duman and Monteggia, 2006) ; it also has multiple non-CNS effects (Wolkowitz et al., 2011) . The "neurotrophin hypothesis of depression" posits that certain central BDNF deficiencies underlie depression, and that antidepressants work via restoration of central BDNF activity (Duman and Monteggia, 2006) . Several studies have found that hippocampal and serum BDNF levels are low in un-medicated depressed patients, and that these levels increase with antidepressant treatment (Bocchio-Chiavetto et al.; Brunoni et al., 2008; Duman and Monteggia, 2006; Gass and Hellweg, 2010; Hashimoto, 2010; Sen et al., 2008) . The neurotrophin hypothesis is further supported by findings that intra-cerebroventricular and intra-hippocampal injections of BDNF produce antidepressant-like effects in animal models of depression (Hoshaw et al., 2005; Shirayama et al., 2002) . Conversely, experimentally lowering brain BDNF (or lowering expression of its high affinity receptor, tyrosine kinase TrkB, in neural progenitor cells in the hippocampus) or inhibiting neurogenesis diminishes antidepressant efficacy in animal models (Adachi et al., 2008; Li et al., 2008; Santarelli et al., 2003) . Still other studies suggest that region-specific expression of BDNF results in different behavioral consequences, as expression of BDNF in the meso-accumbens dopamine system is pro-depressive (Govindarajan et al., 2006; Krishnan and Nestler, 2008) and local knockdown of BDNF in the ventral tegmental area ameliorates the adverse effects of social defeat (Berton et al., 2006; Krishnan et al., 2007) . This raises the possibility that brain region-specific BDNF deficiency (especially in areas of the brain such as the subgranular zone of the dentate gyrus of the hippocampus) may underlie the development of depression in humans, 
